Sveriges Riksbank
RESULT OF RIKSBANK REVERSED AUCTIONS SEK GOVERNMENT BONDS
Auction date | 2021-01-22 |
Loan | 3111 |
Coupon | 0.125 % |
ISIN-code | SE0007045745 |
Maturity | 2032-06-01 |
Tendered volume, SEK mln | 500 +/- 250 |
Volume offered, SEK mln | 1,674 |
Volume bought, SEK mln | 500 |
Number of bids | 14 |
Number of accepted bids | 6 |
Average yield | -1.592 |
Lowest accepted yield | -1.598 |
Highest yield | -1.585 |
% accepted at lowest yield | 33.33 |
Auction date | 2021-01-22 |
Loan | 3112 |
Coupon | 0.125 % |
ISIN-code | SE0008014062 |
Maturity | 2026-06-01 |
Tendered volume, SEK mln | 500 +/- 250 |
Volume offered, SEK mln | 1,450 |
Volume bought, SEK mln | 500 |
Number of bids | 10 |
Number of accepted bids | 3 |
Average yield | -1.727 |
Lowest accepted yield | -1.731 |
Highest yield | -1.719 |
% accepted at lowest yield | 100.00 |
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Sparinvest SICAV9.3.2021 07:31:26 CET | Pressemeddelelse
Opdateret prospekt for Sparinvest SICAV
Innofactor Plc9.3.2021 07:02:10 CET | Press release
Innofactor Plc Annual Report for 2020 has been published
Santhera Pharmaceuticals Holding AG9.3.2021 07:02:00 CET | Press release
Santhera Announces Results of Bondholders’ Meeting
JDE Peet's N.V.9.3.2021 07:01:59 CET | Press release
JDE Peet’s reports full-year results 2020
Novartis Pharma AG9.3.2021 07:01:48 CET | Press release
Novartis provides update on Phase III study evaluating canakinumab (ACZ885) as second or third-line treatment in combination with chemotherapy in non-small cell lung cancer
Hyloris Pharmaceuticals9.3.2021 07:01:38 CET | Press release
Hyloris Reports Full Year 2020 Financial Results
IMCD N.V.9.3.2021 07:01:28 CET | Press release
IMCD to divest its Nutri Granulations Business to J.M. Huber Corporation
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom